Trials / Not Yet Recruiting
Not Yet RecruitingNCT06557031
Clinical Performance Study of the ABTest Card® Device.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Diagast · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study aims to confirm the performance equivalence of the in vitro diagnostic device ABTest Card®REF with the ABTest Card®NEW device.
Detailed description
Following some changes in the ABTest Card® raw materials, a new validation of the associated clinical performances is required. Raw materials of the ABTest Card® are : Triton, Cleanis, Tween, Yellow, Blue dye and the blood segment opener device. According to the regulatory text "Common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council", 90% of the results will be derived from the performance study carried out at the DIAGAST laboratory on tube left over and blood bag, and 10% of the results will be derived from the use of the device in a real situation ("at the bedside"). The Regulation 2017/746 (IVDR) on IVDMD, has been effective since May 2022 with transitional periods. The IVDR replaces the current EU Directive (98/79/EC) to ensure a higher level of health and safety for the making available and putting into service of medical devices on the EU market. As the ABTest Card® is already CE marked under Directive 98/79/EC as List IIA product, this study is part of the device's post-marketing performance monitoring. The purpose of this study is to document and verify the clinical performance of the ABTest Card® device in combination with the new raw materials used for manufacturing (ABTest Card®NEW), by comparing the results obtained with the ABTest Card®REF, already commercialised and used routinely by the study sites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ABTest Card®REF and ABTest Card®NEW | Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device). |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2024-08-16
- Last updated
- 2024-08-16
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06557031. Inclusion in this directory is not an endorsement.